5,402 Shares in Penumbra, Inc. $PEN Acquired by VIRGINIA RETIREMENT SYSTEMS ET Al

VIRGINIA RETIREMENT SYSTEMS ET Al bought a new position in shares of Penumbra, Inc. (NYSE:PEN) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 5,402 shares of the company’s stock, valued at approximately $1,386,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. JPMorgan Chase & Co. grew its position in Penumbra by 437.0% in the first quarter. JPMorgan Chase & Co. now owns 703,634 shares of the company’s stock valued at $188,159,000 after acquiring an additional 572,606 shares in the last quarter. Lord Abbett & CO. LLC acquired a new stake in Penumbra in the first quarter valued at approximately $63,731,000. Los Angeles Capital Management LLC grew its position in Penumbra by 487.1% in the first quarter. Los Angeles Capital Management LLC now owns 179,550 shares of the company’s stock valued at $48,013,000 after acquiring an additional 148,968 shares in the last quarter. Nuveen LLC acquired a new stake in Penumbra in the first quarter valued at approximately $33,696,000. Finally, Woodline Partners LP grew its position in Penumbra by 476.1% in the first quarter. Woodline Partners LP now owns 145,881 shares of the company’s stock valued at $39,010,000 after acquiring an additional 120,558 shares in the last quarter. Institutional investors and hedge funds own 88.88% of the company’s stock.

Insider Buying and Selling

In other Penumbra news, EVP Johanna Roberts sold 600 shares of the firm’s stock in a transaction on Wednesday, October 1st. The stock was sold at an average price of $249.70, for a total value of $149,820.00. Following the sale, the executive vice president directly owned 64,257 shares in the company, valued at approximately $16,044,972.90. This trade represents a 0.93% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Arani Bose sold 12,000 shares of the firm’s stock in a transaction on Wednesday, August 13th. The shares were sold at an average price of $250.65, for a total value of $3,007,800.00. Following the completion of the sale, the director owned 558 shares in the company, valued at $139,862.70. The trade was a 95.56% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 64,460 shares of company stock valued at $16,322,614 in the last three months. 4.20% of the stock is owned by corporate insiders.

Penumbra Stock Performance

Shares of PEN opened at $251.97 on Thursday. The business’s fifty day moving average price is $260.53 and its 200 day moving average price is $261.06. Penumbra, Inc. has a 12-month low of $199.01 and a 12-month high of $310.00. The stock has a market capitalization of $9.83 billion, a PE ratio of 67.01, a price-to-earnings-growth ratio of 2.25 and a beta of 0.41. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.75 and a quick ratio of 4.04.

Penumbra (NYSE:PEN) last posted its earnings results on Tuesday, July 29th. The company reported $0.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.81 by $0.05. The company had revenue of $339.46 million for the quarter, compared to analysts’ expectations of $327.37 million. Penumbra had a return on equity of 11.55% and a net margin of 11.54%.The firm’s quarterly revenue was up 13.4% compared to the same quarter last year. During the same period last year, the business posted $0.64 earnings per share. Penumbra has set its FY 2025 guidance at EPS. Equities research analysts forecast that Penumbra, Inc. will post 3.67 EPS for the current year.

Wall Street Analysts Forecast Growth

PEN has been the subject of several recent research reports. William Blair raised shares of Penumbra to a “strong-buy” rating in a research report on Friday, July 18th. Morgan Stanley raised their price target on shares of Penumbra from $260.00 to $266.00 and gave the stock an “equal weight” rating in a research report on Thursday, July 31st. Evercore ISI decreased their price target on shares of Penumbra from $300.00 to $285.00 and set an “outperform” rating for the company in a research report on Tuesday, October 7th. Citigroup decreased their price target on shares of Penumbra from $320.00 to $285.00 and set a “neutral” rating for the company in a research report on Wednesday, July 9th. Finally, UBS Group set a $335.00 price target on shares of Penumbra and gave the stock a “buy” rating in a research report on Wednesday, July 30th. One analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $302.81.

Penumbra Company Profile

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.